BangBio Secures Nearly RMB 200 Million in Series B+ Financing to Advance Global Cell and Gene Therapy Pipeline
BRL Medicine
Cell and Gene Therapy Drug Developer
On November 22, 2024, BRL Medicine Inc. (hereinafter referred to as "BRL Medicine"), a company focused on gene and cell therapy, announcedCompleted nearly 200 million RMB in B+ round financing。This round of financing was led by CSPC Fund, with BeiGene Fund and other institutions following the investment.After obtaining this round of financing, BRL Medicine will comprehensively advance the clinical transformation and market launch of its multi-pipeline products. It will also intensify efforts to accelerate the global R&D layout of its product pipelines, contributing to the development of life sciences worldwide and bringing hope to patients suffering from genetic disorders, malignant tumors, and autoimmune diseases globally!
BRL Medicine Headquarters
As a leading cell and gene therapy pharmaceutical company in the industry, BRL Medicine Inc., based in Shanghai, has been committed to the fundamental research and development transformation of innovative drugs for many years. Currently, relying on the profound academic accumulation of its core team, BRL Medicine is dedicated to deeply exploring gene-editing transformation scenarios, establishing a solid patent foundation, and transforming its achievements into a potential commercial product pipeline. The company has confirmed good drugability in multiple clinical trials, with 4 projects already approved for IND and officially entering the registration clinical trial stage, while several other projects are in the IND application stage. Among them,Gene Therapy Product for Transfusion-Dependent Beta-Thalassemia —— "BRL-101", is the world's first successful treatment of β through gene editing technology.0/β0The project for severe thalassemia has demonstrated the best clinical outcomes globally, received China's IND approval in August 2022, and officially entered the registration clinical stage. It has successfully helped 15 thalassemia patients worldwide to completely摆脱输血依赖, with the longest time since the first patient achieved “脱贫” now exceeding four years; moreover,CD19-Targeted Non-Viral定点Integration PD1-CAR-T Cell Product —— “BRL-201”, is the world's first team to adopt a revolutionary non-viral technology pathway, significantly reducing the manufacturing cost compared to viral CAR-T products. It also features a shorter preparation cycle, superior clinical outcomes, and a patient complete response rate (CR) as high as 85.7%. It was approved for an IND in China in 2022 and has officially entered the registration clinical stage. To date, the first patient has been cancer-free for over four years; currently, BRL Medicine is based onNon-viral targeted integration PD1-CAR-T for autoimmune diseases has been expanded to include moderate or severe refractory systemic lupus erythematosus (SLE).This indication corresponds to the product.“BRL-203”Also recently approved for IND in ChinaIn addition to the above product pipelines, BRL Medicine has also achieved remarkable results in the UCAR-T project.UCAR-T Product "BRL-301" for B-cell MalignanciesIn 2023, it obtained the IND in China. This product has achieved a comprehensive improvement in efficacy, safety, and clinical accessibility, demonstrating significant industrialization advantages. It targetsAutoimmune DiseasesThe research findings of the brand-new generation of allogeneic universal CAR-T "BRL-303" were also published this year inCell Journal,It is worth mentioning that this is the world's first successful case of using universal CAR-T cell therapy for autoimmune diseases in international reports, and it has been subsequentlyNatureHeadline Report,Nature Reviews RheumatologySelected as a Research Highlight, Recognized by "Father of CAR-T" Professor Carl JuneCellHighly Commented Release.
As the lead investor of this round of financing, CSPC Fund has abundant resources and experience in the pharmaceutical field and is full of confidence in the development prospects of BRL Medicine.Shiyao Fund stated,BRL Medicine is a global leading cell and gene therapy pharmaceutical company, possessing a world-class scientific research team and advanced technology, with multiple products at the forefront internationally and showing great potential. In the future, comprehensive support will be provided to BRL Medicine in the exploration of innovative drug development, with the expectation of jointly creating a diversified product portfolio to benefit patients. We also look forward to collaborating to advance the rapid development of the CGT industry and contribute to innovation in China's pharmaceuticals sector.
At the same time, Beida Fund, as a co-investor, also expressed optimism about the development potential of BRL Medicine.Betta Fund stated,We have been accompanying BRL Medicine's growth and development for a long time, and with this follow-up investment, we not only value its significant position in the industry and continuous innovation in technology development, but also recognize the company’s rarity and unique, hard-to-replicate qualities in the CGT field. We look forward to closer cooperation with BRL Medicine in the future, jointly supporting its greater breakthroughs in the innovative drug sector and providing patients with more and better treatment options.
Regarding the successful completion of this round of financing, CEO of BRL MedicineDr. Zheng BiaoSaid: "We are very grateful to all the investors for their support of BRL Medicine. Today, innovative drugs in the global CGT field are developing rapidly, and this phase is also a crucial opportunity for China's biopharmaceutical industry to ‘overtake on a curve’ in this popular track. As one of the earliest companies globally to engage in gene-editing technology R&D and application, BRL Medicine has always adhered to the concept of fundamental technological innovation and product iteration upgrades, establishing five proprietary technology platforms. In the future, we will continue to rely on our core key technology platforms to comprehensively advance the progress of multiple product pipelines, accelerate the global R&D layout, and facilitate the clinical transformation and implementation of products. We look forward to bringing better treatment options to patients in China and around the world."
BRL Medicine Inc. is committed to becoming a global leading cell and gene pharmaceutical company in the era of new commercial civilization. With the mission of "leading innovation with gene editing technology, developing breakthrough therapies, and benefiting all humanity," BRL Medicine, relying on its self-developed center and the "Shanghai Gene Editing and Cell Therapy Research Center" co-built with universities, has generated more than 100 patent achievements so far. Currently, 19 projects are undergoing clinical trials in more than 20 well-known hospitals, 4 projects have been approved for IND, officially entering the registered clinical trial stage, and several other projects are in the IND application stage. Among them, gene editing treatment for β-thalassemia, non-viral...PD1Targeted integration CAR-T, and UCART projects have achieved excellent clinical results, demonstrating global leadership, and inNature、Cell、Nature Medicine、Nature biotechnology...and published multiple academic papers in well-known academic journals. BRL Medicine has established five proprietary technology platforms: a gene-editing technology innovation platform, a hematopoietic stem cell platform, a non-viral site-specific integration CAR-T platform, a universal cell platform, and an enhanced T-cell platform. With a 7000-square-meter GMP pilot production base and a nearly 100-person operations team, it effectively ensures that innovative research results can be quickly transformed and applied. BRL Medicine continuously drives the rapid updating and iteration of its R&D products based on patient needs and clinical feedback. Upholding an attitude of openness, sharing, and win-win cooperation, BRL Medicine is working with global innovative biopharmaceutical ecosystem companies to accelerate the transformation and implementation of innovative drugs for the benefit of patients worldwide suffering from genetic diseases, malignant tumors, and autoimmune disorders!
E.N.D
Article Recommendation(Click the article title below to open the original text)：
Disclaimer: The content is sourced from the company's official channels. This article aims to share knowledge, and all content is for reference only and does not constitute any advice.